Syndax Pharmaceuticals Inc 2025年度报告

Form 10-KA copy of our Annual Report on Form 10-K Quarterly Reports and Proxy StatementsOur Quarterly Reports on Form 10-Q and for the fiscal year ended December 31, 2025(“2025 10-K”) is included as part of this 2025Annual Report, has been furnished to allstockholderstogether with the proxystatement for the 2026 Annual Meeting ofStockholders, which is scheduled to be heldon June 10, 2026, and is incorporated hereinby reference. Additionally, copies of this2025 Annual Report and the 2025 10-K areavailable without charge on the internet byvisiting the EDGAR section of the Securitiesand Exchange Commission (SEC) website(www.sec.gov/edgar) or the Investors sectionof our website www.syndax.com. We willalso provide a copy of the 2025 10-K withoutcharge,uponwrittenrequestfromstockholdersto Investor Relations at theaddress provided below. proxy statements can be obtained on theinternet by visiting the EDGAR section of theSEC website (www.sec.gov/edgar) or via theInvestorssectionofourwebsitewww.syndax.com or by contacting InvestorRelations. 2026 Annual Meeting of StockholdersJune 10, 2026, 12:00 p.m., Eastern timeVirtual meeting only via webcast atwww.meetnow.global/ MUGAWRX Common Stock ListingNASDAQ Global Select MarketTrading Symbol: SNDX Transfer Agent and RegistrarFidelity InvestmentsAttn: Fidelity Stock Transfer SolutionsPO Box 770017Cincinnati, OH 45277Tel: 1-833-500-1036 The copy of the 2025 10-K that is included aspartof this 2025 Annual Report is notaccompanied by the exhibits that were filedwith the SEC. These exhibits are accessibleonthe internet by visiting the EDGARsectionoftheSECwebsite(www.sec.gov/edgar) or the Investors sectionof our website www.syndax.com. We willfurnish any printed copies of the exhibits tothose stockholders who request copies uponpayment to the Company of its reasonableexpenses in furnishing the exhibits. Requestsfor copies of the exhibits should be made toInvestor Relations at the address providedbelow. Corporate OfficeSyndax Pharmaceuticals, Inc. 730 Third Avenue, Floor 9New York, New York 10017Tel: 781-419-1400www.syndax.com References to websites are inactive textualreferencesonly and the contents of ourwebsite are not incorporated by referenceintothis 2025 Annual Report for anypurpose. Investor RelationsSyndax Pharmaceuticals, Inc. 730 Third Avenue, Floor 9New York, New York 10017Tel: 781-419-1400Email: ir@syndax.com UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORM 10-K (Mark One)ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2025ORTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the Transition Period fromtoCommission File Number: 001-37708 Syndax Pharmaceuticals, Inc.(Exact name of Registrant as specified in its charter) Delaware283432-0162505(State or Other Jurisdiction ofIncorporation or Organization)(Primary Standard IndustrialClassification Code Number)(I.R.S. EmployerIdentification Number)730 Third Avenue, 9th FloorNew York, NY 10017(781) 419-1400(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.YesNo Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Act.YesNo Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to the filing requirements for the past 90 days.YesNo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files).YesNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large Accelerated FilerNon-accelerated FilerEmerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of theeffectiveness of its in